<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00746824</url>
  </required_header>
  <id_info>
    <org_study_id>2022</org_study_id>
    <nct_id>NCT00746824</nct_id>
  </id_info>
  <brief_title>A Study to Determine the Effects of TM30339 on Weight Loss in Obese Individuals.</brief_title>
  <official_title>TM30339: A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel, Repeated Subcutaneous Dose-range Study Designed to Determine the Weight Loss in Obese Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>7TM Pharma A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>7TM Pharma A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effects of TM30339 on weight loss in obese
      individuals after 28 days dosing.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Obesity is a disease with large socioeconomic consequences and many serious health
      consequences including Type 2 diabetes, dyslipidemia and cardiovascular diseases. The
      prevalence of obesity is increasing both in developed and developing countries. There is a
      great need for further medicinal treatments that effectively will support life style changes
      or surgical procedures in reducing or maintaining bodyweight.

      7TM Pharma has identified TM30339 as a clinical development candidate molecule with potential
      to assist in the control and amelioration of obesity in humans.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The IND was withdrawn.
  </why_stopped>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint is the change in body weight from baseline (Visit 1) to Visit 5 (the 29th day),which will be computed for each patient and then averaged for each dose arm.</measure>
    <time_frame>Visit 5 (the 29th day)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the effects of TM30339 after 28 days dosing of obese individuals on: Waist, hip, and waist/hip ratio</measure>
    <time_frame>Visit 5 (the 29th day)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the effects of TM30339 after 28 days dosing of obese individuals on fasting glucose and insulin, and insulin sensitivity index</measure>
    <time_frame>Visit 5 (the 29th day)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the effects of TM30339 after 28 days dosing of obese individuals on formation of antibodies towards the drug, TM30339</measure>
    <time_frame>Visit 5 (the 29th day)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the effects of TM30339 after 28 days dosing of obese individuals on safety and tolerability</measure>
    <time_frame>Visit 5 (the 29th day)</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">192</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AM dose: 0.85 mg
PM dose: placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AM dose: 0.85 mg
PM dose: 0.85 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AM dose: 2.55 mg
PM dose: placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AM dose: placebo
PM dose: 2.55 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AM dose: 2.55 mg
PM dose: 2.55 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AM dose: placebo
PM dose: placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TM30339 and/or placebo</intervention_name>
    <description>The drug and/or placebo will be injected in the abdominal area (site to vary for each injection). Injections will be administered twice daily for 28 days.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
    <arm_group_label>6</arm_group_label>
    <other_name>30339</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Obese males and females with a BMI of 30-40 kg/m2 inclusive and weight in the range of
             85 - 135 kg inclusive

          2. Age 18-60 years inclusive

          3. Stable lifestyle e.g. smoking, exercise and eating patterns and times for at least 6
             months, and willing to maintain these habits during the course of the study

          4. Stable weight over past 2 months i.e. a change in body weight &lt; 3 kg as reported by
             the subject

        Exclusion Criteria:

          1. Subjects with a history of allergies toward products containing natural rubber (e.g.
             latex)

          2. Subjects with, or with a history of, any clinically significant neurological,
             gastrointestinal (including bariatric surgery), renal, hepatic, cardiovascular,
             psychiatric, respiratory, metabolic, endocrine, haematological, or other major
             disorders

          3. Subjects who have a supine blood pressure at screening or Visit 1 higher than 150/95
             mmHg by repeat measurements within 15 minutes

          4. Subjects who have a QTc (Bazett's correction) interval of &gt; 450 msec at screening

          5. Subjects with bradycardia (heart rate &lt; 50)

          6. Subjects with heart block

          7. Clinically significant thyroid dysfunction as evidenced by TSH &gt; 1.5 X ULN
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 27, 2008</study_first_submitted>
  <study_first_submitted_qc>September 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2008</study_first_posted>
  <last_update_submitted>August 31, 2012</last_update_submitted>
  <last_update_submitted_qc>August 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>weight loss</keyword>
  <keyword>7TM Pharma</keyword>
  <keyword>TM30339</keyword>
  <keyword>Y4 receptor antagonist</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

